Detalhe da pesquisa
1.
Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan.
Gastric Cancer
; 26(1): 132-144, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36316527
2.
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.
Gastric Cancer
; 25(1): 207-217, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480657
3.
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.
Int J Clin Oncol
; 27(9): 1450-1458, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35861943
4.
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab.
Gastric Cancer
; 24(4): 946-958, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33743112
5.
Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 for advanced gastric cancer that is refractory to S-1 or S-1 plus CDDP: OGSG0701.
Int J Clin Oncol
; 26(10): 1871-1880, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34453640
6.
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer.
Gastric Cancer
; 23(1): 143-153, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31087200
7.
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.
Gastric Cancer
; 23(3): 510-519, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31863227
8.
Comparison of S-1-cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials.
Int J Clin Oncol
; 25(9): 1635-1643, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32494981
9.
Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
Int J Clin Oncol
; 25(4): 614-621, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31838590
10.
Phase II Trial of 5-Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer.
Oncologist
; 24(2): 163-e76, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30361422
11.
aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Oncologist
; 24(3): 327-337, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30425180
12.
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2).
Gastric Cancer
; 22(2): 344-354, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30506519
13.
Liquid-based endometrial cytology using SurePath™ is not inferior to suction endometrial tissue biopsy for detecting endometrial malignancies: Midterm report of a multicentre study advocated by Japan Association of Obstetricians and Gynecologists.
Cytopathology
; 30(2): 223-228, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30451344
14.
[Outcomes of FOLFIRINOX as First-Line Treatment for Recurrent or Unresectable Pancreatic Cancer].
Gan To Kagaku Ryoho
; 46(8): 1259-1263, 2019 Aug.
Artigo
em Japonês
| MEDLINE | ID: mdl-31501367
15.
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 390(10111): 2461-2471, 2017 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28993052
16.
Randomized, Open-Label Phase II Study Comparing Capecitabine-Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naïve Patients with HER2-Negative Advanced Gastric Cancer: OGSG1105, HERBIS-4A Trial.
Oncologist
; 23(12): 1411-e147, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30115736
17.
Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Oncologist
; 23(1): 7-15, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28894015
18.
First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study.
Gastric Cancer
; 21(5): 792-801, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29353332
19.
What information can change the attitude of teachers toward the human papillomavirus vaccine?
J Obstet Gynaecol Res
; 44(4): 778-787, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29442400
20.
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Int J Cancer
; 141(8): 1682-1689, 2017 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28677116